Logo

Orchid Cellmark Shares Up 16 Percent Despite Wider Q2 Losses and Revenue Decline

Aug 08, 2006
NEW YORK (GenomeWeb News) - Shares in Orchid Cellmark were up approximately 16 percent, or $.33, at $2.45 in mid-afternoon trading today despite the company’s 14-percent decline in revenues and second-quarter loss.
 
As GenomeWeb News reported this morning, Orchid today posted a 14-percent decline in revenues amid mounting losses for the second quarter.
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.